Phenominer Database Results (26 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Method Notes Record ID Study ID
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 100.0 % in vivo visual assessment 0.0 0 70192 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 14.0 d 1.06 5.5 in vivo visual assessment 0.0 0 70194 1301
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91 days-112 days 22 82.0 % in vivo visual assessment 0.0 0 visual observation 69487 837
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 100.0 % in vivo visual assessment 0.0 0 84465 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 91.7 % in vivo visual assessment 0.0 0 84466 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 14.6 d 1.39 6.8 in vivo visual assessment 0.0 0 84467 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 16.3 d 0.94 2.3 in vivo visual assessment 0.0 0 84472 1301
DA/ZtmKini inguinal lymph node wet weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. inguinal lymph node mass male 0 days 8 0.68 g/kg 0.07 0.21 post excision weight measurement 0.0 0 84927 1301
DA/ZtmKini spleen weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. spleen mass male 0 days 8 0.18 % 0.0 0.01 post excision weight measurement 0.0 0 84931 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 12.2 d 0.18 0.4 in vivo visual assessment 0.0 0 70196 1301
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 12 19.7 d 2.48 8.6 in vivo visual assessment 0.0 0 69376 837
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 14.6 d 0.63 3.1 in vivo visual assessment 0.0 0 84468 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 93.0 % in vivo visual assessment 0.0 0 84469 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 14.9 d 1.52 5.9 in vivo visual assessment 0.0 0 84471 1301
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 12 14.8 d 2.4 8.3 in vivo visual assessment 0.0 0 69491 837
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 15.6 d 9.4 in vivo visual assessment 0.0 0 69499 837
DA/ZtmKini plasma orosomucoid 1 level Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. orosomucoid 1 amount male 0 days 8 419.0 mg/l 82.02 232.0 radial immunodiffusion assay 0.0 0 84929 1301
DA/ZtmKini thymus weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. thymus mass male 0 days 8 0.6 mg/g 0.07 0.19 post excision weight measurement 0.0 0 84932 1301
DA/ZtmKini liver weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. liver mass male 0 days 8 28.96 g/kg 0.64 1.8 post excision weight measurement 0.0 0 84933 1301
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 22 15.8 d 1.9 8.9 in vivo visual assessment 0.0 0 69489 837
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 22 19.6 d 2.22 10.4 in vivo visual assessment 0.0 0 69493 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 20.0 d 8.5 in vivo visual assessment 0.0 0 69501 837
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 100.0 % in vivo visual assessment 0.0 0 84470 1301
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 12 92.0 % in vivo visual assessment 0.0 0 68122 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 0 89.0 % 33.0 in vivo visual assessment 0.0 0 visual observation 69497 837
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 96.3 % in vivo visual assessment 0.0 0 70188 1301